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The role of histamine H3 receptors (H3Rs) in the regulation of gastroprotection and 
production of prostaglandin E2 (PGE2) as well as somatostatin remains contradictory. 
Therefore, the effects of the H3R antagonist/inverse agonist M39 on in vivo acidified 
ethanol-induced gastric ulcers and gastric acid secretion in the C57BL/6 mice were 
assessed. Results showed that acute systemic administration of H3R agonist (R)-α-
methylhistamine (RAMH, 100 mg/kg, i.g.) significantly reduced the severity of ulcer 
index, increased gastric acid output, and increased mucosal PGE2 production 
without any alteration of somatostatin concentration in gastric juice. However, only 
acute systemic administration of the H2R agonist dimaprit (DIM, 10 mg/kg, p.o.) 
significantly decreased the level of somatostatin measured in gastric juice. Moreover, 
acute systemic administration of M39 (0.3 mg/kg, i.g.) abrogated the RAMH-induced 
increase of acid output as well as PGE2 production, but not the DIM (10 mg/kg, 
i.g.)-stimulated acid secretion, indicating that RAMH as well as M39 modulate the 
gastroprotective effects through interactions with histamine H3Rs. The present 
findings indicate that agonistic interaction with H3Rs is profoundly involved in the 
maintenance of gastric mucosal integrity by modulating PGE2 as well as gastric 
acid secretion, with no apparent role in the regulation of the inhibitory influence of 
somatostatin.
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INTRODUCTION
Peptic ulcer is a chronic disease affecting up to 10% of the world’s population, and the formation of 
peptic ulcers depends on the presence of increased acidic gastric juice and the decreased mucosal 
defenses (Kuna et al., 2019). Non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori 
(H. pylori) infection are the two main factors disrupting the mucosal resistance to injury. Currently 
available conventional treatments of peptic ulcers include numerous pharmaceutical agents such as 
proton pump inhibitors, histamine H2-receptor antagonists, anticholinergics, antacids, antimicrobial 
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agents, sucralfate, and bismuth, all of which are not fully effective, 
and are associated with numerous side effects including impotence, 
arrhythmia hematopoietic alterations hypersensitivity and 
gynecomastia (Chanda et al., 2011; Palle et al., 2018). Consequently, 
there is still a strong need for new pharmacologically active entities 
for the therapeutic management of peptic ulcer. Histamine exerts 
its biological activities through interaction with four distinct 
histamine receptors (H1R–H4R) that belong to the G-protein 
coupled receptor (GPCR) family (Lovenberg et al., 1999; Panula 
et al., 2015; Sadek and Stark, 2015; Sadek et al., 2016b). H1R and 
H2R are found in the brain and periphery. Although H4Rs are 
present in the brain, they are predominately expressed in mast cells 
and leucocytes, whereas H3Rs are abundant in CNS (Arrang et al., 
1983; Arrang et al., 1985; Arrang et al., 1987a; Arrang et al., 1987b; 
Arrang et al., 1988; Arrang et al., 2007; Panula et al., 2015). H3Rs 
are coupled to Gi/Go- proteins and act as auto-receptors that control 
the synthesis and release of histamine in the CNS, while activation 
of H1R and H2R mediates slow excitatory postsynaptic potentials 
(Arrang et al., 1983; Arrang et al., 1985; Arrang et al., 1987b; 
Sadek and Stark, 2015). Furthermore, H3Rs functioning as hetero-
receptors can also regulate the release of other neurotransmitters 
like acetylcholine, glutamate, GABA, norepinephrine, serotonin, 
dopamine in variable brain regions (Brown et al., 2001). Mounting 
preclinical experimental evidences related numerous functional 
and behavioral effects to central H3R-mediation. The activation 
of such cerebral sites appears to stimulate a waking effect in cats 
(Schwartz et al., 2003; Lin et al., 2008; Lin et al., 2011), modulation 
of locomotor activity, anticonvulsant, antinociceptive, and 
procognitive actions in mice and rats (Clapham and Kilpatrick, 
1993; Yokoyama et al., 1993; Clapham and Kilpatrick, 1994; 
Malmberg-Aiello et al., 2003; Sadek et al., 2013; Sadek et al., 2014a; 
Sadek et al., 2014b; Sadek et al., 2015; Sadek and Stark, 2015; Sadek 
et al., 2016a; Sadek et al., 2016b; Sadek et al., 2016c). Interestingly, 
several polymorphisms have been detected for H3Rs (Hancock 
et al., 2003; Bongers et al., 2007), and H3Rs were found to be 
expressed in dimers (Shenton et al., 2005; Bakker et al., 2006) as 
well as co-expressed with other GPCRs, e.g. dopamine D1- or D2 
receptors and adenosine A2A receptors in form of heteromers, 
and were linked with their modulating effects on several brain 
neurotransmitters, and therefore, their influence in mitigating 
numerous brain disorders (Ferrada et al., 2008; Ferrada et al., 
2009; Moreno et al., 2011; Rodriguez-Ruiz et al., 2017; Marquez-
Gomez et al., 2018). Notably, complexity of histamine H3R biology 
e.g. many isoforms, constitutive activity, the aforementioned 
heteromerization with other receptors (dopamine D2, D1, 
adenosine A2A), and pharmacology make it difficult to realize and 
evaluate the therapeutic potential of H3R antagonists (Lazewska 
and Kiec-Kononowicz, 2018).
Moreover, H3R has been identified in the gastrointestinal tract 
of the rat by immunohistochemistry, as immunoreactivity to H3R 
was exclusively localized to the endocrine cells scattered in the 
gastrointestinal mucosa, with positive cells being prominently 
abundant in the gastric fundus, while they were rarely found in 
the other regions (Grandi et al., 2008). 
Contrary, peripheral administration of the selective H3R 
agonist (R)-α-methylhistamine (RAMH) was found to inhibit 
pentagastrin-, 2-deoxy-D-glucose-, and peptone meal-stimulated 
gastric acid secretion in conscious cats as well as pentagastrin- and 
bombesin-induced hypersecretion in the conscious dog (Bado 
et al., 1991; Soldani et al., 1993). The latter inhibitory effects were 
also found to be antagonized by co-administration of the H3R 
antagonist thioperamide (Soldani et al., 1993). Moreover, numerous 
previous in-vitro experimental models of gastric injury showed that 
H3R agonist RAMH exerts protective effects with controversial 
interpretations (Morini et al., 1995a; Morini et  al., 1995b; Morini 
et al., 1997; Morini et al., 2008b). For instance, RAMH was likely 
to inhibit acid secretion via the suppression of histamine in isolated 
rat fundic enterochromafin-like cells, whereas an increased acid 
secretion secondary to reduced somatostatin secretion is reported in 
isolated mouse stomach (Morini et al., 1995a; Morini et al., 1995b; 
Morini et al., 1997; Morini et al., 2008b). Furthermore, early in-vivo 
experiments showed that RAMH also potently inhibits gastric 
secretion by a number of indirect stimuli, e.g. vagal stimulation or 
pentagastrin (Bado et al., 1991; Yokotani et al., 2000). In addition, 
the role of H3Rs in the gastric mucosal gastrin expression and 
release by inhibiting secretion of somatostatin is still unclear, since 
the mechanism of action underlying this phenomenon remains 
unknown and is still a matter of study even though the presence of 
H3Rs on parasympathetic nerve terminals or on gastric paracrine 
cells has been proposed (Soll and Walsh, 1979; Bado et al., 1991; 
Soldani et al., 1993; Soldani et al., 1994; Coruzzi et al., 2001). In 
addition, unclear data were obtained with two highly selective H3R 
agonists, namely imetit (Garbarg et al., 1992) and immepip (Vollinga 
et al., 1994), which failed to share the gastroprotective effect of 
RAMH towards 0.6 N HCl-induced gastric damage in rat. However, 
it is well-known that many imidazole-containing ligands, including 
immepip and imetit, display affinity for the H4R (Lim et al., 2005), 
indicating that it might be postulated that histamine H4 receptor-
mediated mechanisms may have influenced the interpretation of the 
observed results for immepip and imetit (Coruzzi et al., 2011). The 
H4R was primarily identified on immunocompetent cells and cells of 
the hematopoietic lineage, such as mast cells, eosinophils, basophils, 
dendritic cells and T cells and a primary role in the inflammatory 
responses was postulated (Leurs et  al., 2009). Therefore, H4R 
antagonists are under development as novel antiallergic and anti-
inflammatory drugs (Thurmond et al., 2008; Zampeli and Tiligada, 
2009; Sadek and Stark, 2015). Additionally, H4R expression was 
detected by immunohistochemistry in different areas of the gut 
(Cianchi et al., 2005; Sander et al., 2006; Breunig et al., 2007; Boer 
et al., 2008; Morini et al., 2008a) and protective effects have been 
evidenced, by the use of the H4R antagonist JNJ7777120 in various 
rodent models of gastric and intestinal damage (Thurmond et al., 
2004; Varga et al., 2005; Coruzzi et al., 2007), demonstrating the 
involvement of the H4Rs in gastrointestinal inflammation and 
ulcerogenesis (Coruzzi et al., 2012).
 To date, the potential contribution of a central H3R-mediated 
in-vivo regulatory influence in affecting gastric acid secretion 
has not been extensively explored and as a result cannot be 
ruled out completely. The latter considerations together with 
the aforementioned controversies in results obtained so far 
encouraged us to investigate the possible involvement of H3Rs in 
the control of gastric secretory function. Therefore, the objective 
of the current study was to determine whether interactions with 
H3Rs mediate in vivo gastroprotection applying the acidified 
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ethanol-induced gastric ulcers and gastric acid secretion model 
in C57BL/6 mice, and following intragastric (i.g.) administration 
of the potent and selective H3R antagonist/inverse agonist M39 
in presence and absence of the selective and potent H3R agonist 
RAMH (Figure 1). Furthermore, the modulating effects of 
both H3R compounds on synthesis of somatostatin as well the 
production of prostaglandin E2 (PGE2) were investigated. 
MATERIAL AND METHODS
Animals
C57BL/6 mice were purchased from Jackson Laboratory, Boulevard, 
Bethesda, MD 20892-4874, USA. They were bred at our animal 
facility. Adult male C57BL/6 mice (14–15 weeks) weighing 25–28 g 
were fasted for 24 h in wire mesh cages to avoid coprophagy but had 
free access to water ad libitum. The temperature of the animal room 
were maintained at 22 ± 2°C and with a 12–12 h dark–light cycle. 
This study was carried out in accordance with the recommendations 
of the European Communities Council Directive of 24 November 
1986 (86/609/EEC), and was approved by the Institutional Animal 
Ethics Committee in the College of Medicine and Health Sciences/
United Arab Emirates (Approval No. A38-13). All efforts were 
made to minimize animal suffering and to reduce the number of 
animals used.
Chemicals and Drugs
The H3R antagonist/inverse agonist 3-(1H-imidazol-4-yl)
propyl but-3-en-1-ylcarbamate (M39) was synthesized by us 
in the Department of Technology and Biotechnology of Drugs 
(Kraków, Poland) as described previously (Wiecek et al., 2011) 
(Figure 1). The compound M39 was synthesized by a modified 
Curtius reaction. In this reaction 4-pentenoic acid was reacted 
with diphenyl phosphorazidate (DPPA) under basic conditions 
leading to in situ obtained isocyanate intermediate, which then 
was reacted with 3-(1H-imidazol-yl)propanol hydrochloride to 
yield M39 (Wiecek et al., 2011).
All other drugs and chemicals were purchased from Sigma-
Aldrich (St Louis, Missouri, USA). All drug solutions were freshly 
prepared. The enzyme immunoassay kit of Somatostatin was 
purchased from Phoenix Pharmaceuticals, Inc., Burlingame, CA 
94010, USA. Enzyme immunoassay kit of PGE2 was purchased 
from R&D Systems, Minneapolis, MN, USA. 
Gastric Acid Secretion In Vivo
Mice were initially anaesthetized with pentobarbitone (70 mg/
kg) intraperitoneally (i.p.). Following general anesthesia, the 
pylorus was ligated according to the method of Shay et  al, 
1945 (Shay et al., 1945; Wiecek et al., 2011). Briefly, after the 
ligation, the animals were assigned into six different groups of 
six mice as follows: group 1: control, pretreated with distilled 
water (DW), group 2: RAMH (100 mg/kg, i.g.), group 3: 
H2R agonist DIM (10 mg/kg, i.g.), group 4: M39 (0.3  mg/
kg, i.g.), group 5: M39 (0.3 mg/kg, i.g.)+RAMH (100 mg/kg, 
i.g.), and group 6: M39 (0.3 mg/kg, i.g.)+DIM (10 mg/kg, i.g.).
All the drug solutions were administered to the animals 
by gastric gavage. However, both groups 5 and 6 received 
H3R antagonist/inverse agonist M39 (0.3 mg/kg) followed by 
15 min later administration of RAMH or DIM, respectively. 
The dose of 0.3 mg/kg of M39 was selected based on a dose 
response (0.3–3.0 mg/kg) pilot study as well as according to 
previous study conducted in Wistar rats (Morini et al., 2000). 
After 4 h, the animals were sacrificed by cervical dislocation 
and the gastric juice was collected for somatostatin assay 
and gastric contents were titrated against 0.01M sodium 
hydroxide for acid output which was calculated and expressed 
as mmol/4h.
Assay of Somatostatin in Gastric Juice
Competitive Enzyme immunoassay of somatostatin in 
gastric juice was performed according to manufacturer’s 
protocol. Briefly, the immunoplate was pre-coated with 
secondary antibody and the nonspecific binding sites were 
blocked. The secondary antibody was allowed to bind to the 
Fc fragment of the primary antibody whose Fab fragment 
was competitively bound by both biotinylated peptide and 
peptide standard or targeted peptide in samples during 2 
incubation at room temperature (20–23°C) on orbital shaker 
at 300–400 rpm. The interaction of biotinylated peptide with 
streptavidin–horseradish peroxidase (SA–HRP) was catalyzed 
by the substrate solution. The intensity of the color is directly 
proportional to the amount of biotinylated peptide– SA–HRP 
complex but inversely proportional to the amount of the 
peptide in standard solutions or samples. The color intensity 
was read at 450 nm with a microplate reader (Tecan Group 
Ltd., Männedorf, Switzerland). Somatostatin concentration was 
expressed as nanogram per ml of gastric juice.
FIGURE 1 | Structure, in-vivo potency, and in-vitro antagonist affinities of 
H3R antagonist/inverse M39. aValues previously published (Wiecek et al., 
2011; Sadek et al., 2013). Values for H1R and H2R were tested on guinea 
pig (gp).
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Gastric Acid Ulcer In Vivo
Acidified ethanol (AE; 60% ethanol in 150 mM hydrochloric 
acid) was used to induce gastric ulcers in the mice. The mice 
were divided into four different groups of 6 animals each. Each 
group received either DW (control), or RAMH (100 mg  kg), 
or M39 (0.3 mg/kg) 15 min prior to RAMH (100 mg/kg) 
administration as a gastric gavage. After 30 min of DW or drug 
administration, AE was given orally to each animal at a dose 
of 0.2 ml per mouse and the animals were killed 1 h later by 
cervical dislocation. The abdomen was incised and the stomach 
removed. The stomach was cut open along the greater curvature 
and rinsed with saline to remove any adherent food particles 
and mucus. The opened stomach was then spread on a sheet 
of cork so as to have a clear macroscopic view of the gastric 
mucosa. The total lengths of the haemorrhagic lesions, which 
were approximately 1 mm in width and formed in the glandular 
portion of the gastric mucosa, were taken as ulcer index (UI). 
An observer unaware of the drug treatments confirmed the ulcer 
index. The use of 60% ethanol in 150 mM HCl as an ulcerogenic 
agent was based on our earlier observation and of others that 
ethanol 50% and over provided a reproducible model of gastric 
damage (Nishida et al., 1994; Mercer et al., 1995; Chandranath 
et al., 2002; Bastaki et al., 2003).
Preparation of Gastric Mucosal Homogenate
Briefly, after dissection, stomachs were washed with ice-cold PBS, 
and the gastric mucosa was rapidly scraped from the underlying 
tissue layers of stomach on ice. The mucosa was weighed, minced 
by forceps, and homogenized with 3 volumes of cold phosphate 
buffer (PBS 0.1 mol/L, pH 7.4, containing 1 mM EDTA and 10 μM 
indomethacin) per gram of tissue using a polytron homogenizer 
(IKA laboratory, Germany).
Assay of PGE2 in Gastric Mucosa
Competitive Enzyme immunoassay of PGE2 in gastric mucosal 
was performed according to manufacturer’s protocol. This 
assay was based on the forward sequential competitive binding 
technique in which PGE2 present in a sample competed with 
horseradish peroxidase (HRP)-labeled PGE2 for a limited 
number of binding sites on a mouse monoclonal antibody. PGE2 
in the sample was allowed to bind to the antibody in the first 
incubation of one hour at room temperature on a horizontal 
orbital microplate shaker (0.12” orbit) at 500 ± 50 rpm. During 
the second incubation, HRP-labeled PGE2 was bound to the 
remaining antibody sites. Unbound materials were washed 
and substrate solution was added to the wells to determine the 
bound enzyme activity. The color development was stopped, and 
the absorbance was read at 450 nm. The intensity of the color 
was inversely proportional to the concentration of PGE2 in the 
sample. PGE2 concentration was expressed as picogram per 
milligram of mucosal tissue.
Statistical Analysis
Data was analyzed statistically using SPSS 25.0 software 
(IBM Middle East, Dubai, UAE). The means of the data are 
presented with the standard error mean (SEM). The results were 
analyzed using independent t-test to determine the significance 
of the mean between the groups. Values of P < 0.05 were 
considered significant.
RESULTS
Acidified Ethanol-Induced Gastric 
Mucosal Lesions
Macroscopy
Acidified ethanol determined the formation of red to black linear 
streaks in the glandular portion of the stomach of vehicle-treated 
group (ulcer index of 35.5 ± 4, n=6) (Figures 2 and 3). Mucosal 
damage caused by acidified ethanol was substantially reduced by 
RAMH at the dose of 100 mg/kg (ulcer index of 6.0 ± 1.46, n = 6; 
P < 0.001). Similarly, M39 when administered alone at a dose 
of 0.3 mg/kg significantly reduced the mucosal damage (ulcer 
index of 9.0 ± 1.41, n = 6; P < 0.001) (Figures 2 and 3). However, 
RAMH and M39 (0.3 mg/kg) failed to completely abrogate each 
other’s protections when compared to vehicle-, RAMH(100mg/
kg)-, M39(0.3mg)-group with ulcer index of 15.67 ± 1.44, n = 6; 
both P < 0.05 for RAMH(100mg)+M39(0.3mg)-treated group 
versus RAMH- or M39(0.3mg)-treated group) (Figures 2 and 3).
PGE2 Synthesis
The observed results show that both the H3R agonist RAMH 
(100 mg/kg) and M39 (0.3 mg/kg) administered separately 
significantly increased the synthesis of mucosal PGE2 with values 
of 38971.17 ± 624.44 and 37828.98 ± 782.45 pg/mg of gastric 
mucosa, respectively (P > 0.001 for RAMH- and M39-treated 
group versus vehicle-treated group), respectively. However, 
co-administration of both M39 and RAMH abrogated each other’s 
stimulating effect on PGE2 synthesis with a value of 26650.72 ± 
3068.16 pg/mg (p = 0.65 for M39+RAMH-treated group versus 
vehicle-treated group) (Figure 4).
Somatostatin Synthesis
The results observed show that only DIM significantly decreased the 
synthesis of somatostatin (12.83 ± 0.36 ng/mL for vehicle-treated 
group versus 9.21 ± 1.25 ng/mL for DIM-treated group; P < 0.05). 
However, RAMH and M39 (0.3 and 3 mg) failed to modulate the 
biosynthesis of somatostatin with values of 12.47 ± 1.33, 13.18 
± 0.80, and 11.21 ± 1.10, respectively (all P values > 0.05) (Figure 5).
Gastric Acid Secretion
In the juice present in the stomach, the H2R agonist DIM and 
the H3R agonist RAMH caused a significant increase in the 
volume of gastric juice with a concomitant marked and significant 
increase in the amount of titratable acidity (Figure 6). The 
stimulation of acid secretion by RAMH, was completely reversed 
by prior treatment with the H3R antagonist/inverse agonist M39 
(p = 0.96 for vehicle-treated group versus RAMH+M39(0.3mg)-
treated group) (Figure 6). However, M39 (0.3 mg/kg) failed to 
reverse the effect observed by DIM (p = 0.63 for DIM-treated 
group versus DIM+M39(0.3mg)-treated group) (Figure 6). In 
addition, H3R antagonist/inverse agonist M39 (0.3 and 3 mg/kg) 
H3Rs Involvement in Gastroprotection and PGE2 ProductionBastaki et al.
5 September 2019 | Volume 10 | Article 966Frontiers in Pharmacology | www.frontiersin.org
had no  effect  on  titratable acidity when administered alone 
as compared to vehicle-treated group (p= 0.36 and p= 0.36, 
for M39(0.3mg)-treated group versus vehicle-treated group 
and M39(3mg)-treated group versus vehicle-treated group, 
respectively) (Figure 6).
DISCUSSION
The current study indicates that RAMH efficiently preserves the 
integrity of mice gastric mucosa against damage with acidified 
ethanol, as measured using macroscopic evaluation (Figure 2). 
In the current in-vivo gastric ulcer model, the H3R agonist 
FIGURE 2 | Photomicrographs of stomachs showing the effect of vehicle, H3R agonist (R)-α-methylhistamine, and test compound M39 on stomach ulcer of 
C57BL/6 mice. Micrographs are the results of five to six such experiments. showing the effect on acidified ethanol in (A) vehicle-, (B) RAMH(100mg/kg)-, (C) 
M39(0.3mg)-, and (D) M39(0.3mg)+RAMH(100mg)-treated group in reducing the stomach ulcers.
FIGURE 3 | Effects of vehicle, H3R agonist (R)-α-methylhistamine, and test 
compound M39 on acidified ethanol-induced ulcer index in C57BL/6 mice. 
**P < 0.01 vs. vehicle-treated group. ***P < 0.001 vs. vehicle-treated group. 
#P < 0.05 vs. RAMH- or M39(0.3mg)-treated group. Data represent mean ± 
SEM (n = 5–6).
FIGURE 4 | Effect of vehicle, H3R agonist (R)-α-methylhistamine, and test 
compound M39 on PGE2 synthesis in the stomach mucosa of C57BL/6 
mice. ***P < 0.001 vs. vehicle-treated group. #P < 0.05 vs. RAMH- or 
M39(0.3mg)-treated group. Results are expressed as the mean ± standard 
error of six replicates.
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RAMH and the H3R antagonist/inverse agonist M39 exhibited 
comparable gastroprotective effects as obviously observed by 
ulcer indices (Figure 3). Moreover, the results observed show 
that the gastroprotective effect provided by H3R agonist RAMH 
was partly reversed when mice were pretreated with M39 as 
measured on the level of ulcer index, indicating that, in addition 
to histaminergic pathways through activation of H3Rs, the 
protective effects might be attributed to mechanisms other than 
histaminergic neurotransmission. These results are in agreement 
with a previous study which showed that H3R is involved in the 
protection of rat stomach against concentrated hydrochloric acid. 
However, the functional role of the H4R is still to be defined, 
although selective agonists induce proulcerogenic effects under 
hydrochloric acid challenge (Coruzzi et al., 2011). Furthermore, 
both compounds when administered separately significantly 
increased the level of synthesized PGE2, an effect that might 
explain the gastroprotection provided by both compounds 
(Figure 4). Interestingly, the stimulating effect observed for 
RAMH on PGE2 synthesis was completely abolished when mice 
were pretreated with the potent H3R antagonist M39 (Figure 4). 
However, the H3R agonist RAMH as well as the H3R antagonist/
inverse agonist M39 failed in the current study to modify the 
synthesis of somatostatin (Figure  5). The latter results are 
in disagreement with previous studies in which modulation 
of H3Rs resulted in a significant alteration of somatostatin 
synthesis, demonstrating that the mechanisms responsible for 
the protective action observed for RAMH and H3R antagonist/
inverse agonist M39 appear to be unrelated to their effects on 
somatostatin synthesis (Morini et al., 1995a; Morini et al., 1995b; 
Morini et  al., 1997; Morini et al., 2000). Moreover, protection 
by RAMH is not attributable to a modulation in gastric acidity, 
since RAMH increased acid production and secretion, although 
significantly lower than the effect observed for the H2R agonist 
DIM (Figure 6). Furthermore, the H3R antagonist/inverse 
agonist M39 failed to modify gastric acid secretion which is in 
agreement with previous studies in which ciproxifan was found to 
be not effective in increasing or decreasing gastric acid secretion 
(Morini et al., 2000). Interestingly, the effect of RAMH, but not 
of DIM, on increasing gastric acid secretion was completely 
abrogated when mice were pretreated with M39 (Figure 6). These 
observations clearly indicate that there is no association between 
the effects observed for RAMH and M39 on gastric acid secretion 
and their influence on the susceptibility of the mucosa to lesion 
formation. Notably, there is still some debate as to whether the 
stimulation of gastric acid secretion evoked by RAMH in rodents 
is attributable to H3R activation (Vuyyuru and Schubert, 1997; 
Coruzzi and Bertaccini, 1998). However, the present failure 
of H3R antagonist/inverse agonist M39 to influence RAMH-
stimulated acid secretion at doses causing a complete inhibition 
of RAMH-induced increase of PGE2 synthesis appears to rule 
out the involvement of H3Rs in the acid secretory response to 
RAMH. Therefore, caution is required when interpreting the 
effects observed for H3R agonists or antagonists/inverse agonists 
in preclinical ulcer models. Accordingly, the differences in animal 
species together with the type of experimental conduct and the 
routes by which the test compounds are administered should be 
considered for comparison when interpreting results observed. 
Additionally, it should be taken into consideration that RAMH 
and M39 are likely to differ significantly in their pharmacokinetic 
properties when it comes to testing them in in-vivo models. 
CONCLUSION
The partial M39-provided inhibition of the gastroprotection 
exerted by RAMH validate the hypothesis that RAMH is capable 
of counteracting mucosal damage mediated through histamine 
H3Rs. However, here we present the first evidence that agonistic 
FIGURE 5 | Effects of vehicle, H2R agonist dimaprit, H3R agonist 
(R)-α-methylhistamine, and test compound M39 on gastric somatostatin 
concentration in C57BL/6 mice. Data represent mean ±SEM (n = 5–6). *P < 
0.05 vs. vehicle-treated group.
FIGURE 6 | Effects of vehicle, H2R agonist dimaprit, H3R agonist (R)-α-
methylhistamine, and test compound M39 on gastric acid secretion in the 
stomachs of C57BL/6 mice. Data represent mean ±SEM (n = 5–6). *P < 
0.05 vs. vehicle-treated group. ***P < 0.001 vs. vehicle-treated group. 
#P < 0.05 vs. RAMH-treated group.
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interaction with H3Rs are actively involved in the maintenance 
of gastric mucosal integrity by modulating PGE2 as well as 
gastric acid secretion, with no apparent role in the regulation 
of inhibitory influence of somatostatin. However, the observed 
results showed that M39 reverses the effects of RAMH on 
gastroprotection and PGE2 production, demonstrating that it 
is still difficult to provide a conclusion since both compounds 
were able to show effects on their own, and combination of 
both counteracts the effects of either alone. Therefore, the exact 
mechanistic background for the mediated protective effects of 
RAMH as well as M39 still continues to be a challenge.
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